Skip to main content

Emerging agents and regimens for cancer therapy 2020

This Journal of Hematology & Oncology collection is the 2020 version of an annual series on emerging agents and regimens for cancer therapy.

The series, which is no longer open for submissions, will include research and review papers on novel agents, first-in-human clinical trials, and regimens for different cancer types.

For published articles in "Emerging agents and regimens for cancer therapy 2019," see here.

New Content Item


  2. Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and cha...

    Authors: Yi-Chao Zheng, Yan-Jia Guo, Bo Wang, Chong Wang, M. A. A. Mamun, Ya Gao and Hong-Min Liu

    Citation: Journal of Hematology & Oncology 2021 14:57

    Content type: Review

    Published on:

  3. Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogenei...

    Authors: Hongtao Liu

    Citation: Journal of Hematology & Oncology 2021 14:49

    Content type: Review

    Published on:

  4. Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibito...

    Authors: Anwaar Saeed, Robin Park and Weijing Sun

    Citation: Journal of Hematology & Oncology 2021 14:13

    Content type: Review

    Published on:

  5. Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activat...

    Authors: Sizhe Liu, Vasiliy Galat, Yekaterina Galat4, Yoo Kyung Annie Lee, Derek Wainwright and Jennifer Wu

    Citation: Journal of Hematology & Oncology 2021 14:7

    Content type: Review

    Published on:

  7. T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. ...

    Authors: Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak and Grzegorz K. Przybylski

    Citation: Journal of Hematology & Oncology 2020 13:176

    Content type: Review

    Published on:

  8. As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and t...

    Authors: Liang Wang, Lin-rong Li and Ken H. Young

    Citation: Journal of Hematology & Oncology 2020 13:175

    Content type: Review

    Published on:

  9. Cell death escape is one of the most prominent features of tumor cells and closely linked to the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic family member myeloid ...

    Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers

    Citation: Journal of Hematology & Oncology 2020 13:173

    Content type: Review

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:31

  10. Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative ...

    Authors: Sangeetha Venugopal and John Mascarenhas

    Citation: Journal of Hematology & Oncology 2020 13:162

    Content type: Review

    Published on:

  12. The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplant...

    Authors: Yang Yang, Yi Li, Huiyao Gu, Mengmeng Dong and Zhen Cai

    Citation: Journal of Hematology & Oncology 2020 13:150

    Content type: Review

    Published on:

  13. Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-rib...

    Authors: Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong and Tian Zhang

    Citation: Journal of Hematology & Oncology 2020 13:144

    Content type: Review

    Published on:

  14. Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous s...

    Authors: Walter Hanel and Narendranath Epperla

    Citation: Journal of Hematology & Oncology 2020 13:79

    Content type: Review

    Published on:

  15. Recent years have witnessed major advances that have improved outcome of adults with acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual disease has fine-tuned our prognosti...

    Authors: Bachar Samra, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian and Nicholas J. Short

    Citation: Journal of Hematology & Oncology 2020 13:70

    Content type: Review

    Published on:

  16. Insulin-like growth factors (IGFs) play important roles in mammalian growth, development, aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and tumor progression, thus providing...

    Authors: Hui Hua, Qingbin Kong, Jie Yin, Jin Zhang and Yangfu Jiang

    Citation: Journal of Hematology & Oncology 2020 13:64

    Content type: Review

    Published on:

  17. Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport ...

    Authors: Nancy G. Azizian and Yulin Li

    Citation: Journal of Hematology & Oncology 2020 13:61

    Content type: Review

    Published on:

  18. Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playi...

    Authors: Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi and Lufeng Zheng

    Citation: Journal of Hematology & Oncology 2020 13:60

    Content type: Review

    Published on: